NCT07413939
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07413939
Title RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive (BREnnA)
Acronym BREnnA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
Hopital du Saint Sacrement RECRUITING Québec Quebec G1S 4L8 Canada Details
Taichung Veterans General Hospital RECRUITING Taichung 407219 Taiwan Details
National Cheng Kung University Hospital RECRUITING Tainan 00704 Taiwan Details
National Taiwan Uni Hospital RECRUITING Taipei 10041 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field